As previously stated, my July blood test results showed that my cancer levels (m-protein) have spiked to very high levels (May = 20; June = 25; July = 31 – 32). So my Myeloma Specialist has added dexamethasone (dex) to my chemo treatment of Ninlaro and Pomalyst. If m-protein = 0, then no cancer/myeloma is detected in my bloodstream. From January 2015 – July 2017, dex was very effective in keeping my cancer levels low and stable. It was stopped, due to eye damage, as my eyes are sensitive to steroids.
On the recommendation of my Glaucoma Specialist, I now have an Optometrist to regularly monitor my eye pressure and help ensure that dex doesn’t cause further eye damage from long-term use. I also remain on Lumigan eye drops, prescribed by my Glaucoma Specialist to help keep my eye pressure normal.
I’m not a fan of dex. I don’t like my moon face or how it enhances my chronic fatigue. Dex makes everyday thinking and doing much more challenging. However, I believe it will my lower cancer levels, so I’m ready for anything.
On Sunday, July 29th, I completed Cycle 46 Week 1. I have multiple myeloma and anemia, a rare cancer of the immune system. Multiple myeloma affects the plasma cells, a type of immune cell that produces antibodies to fight infection. These plasma cells are found in the bone marrow. As a blood cancer, it is incurable, but treatable. Since February 9th 2015, I have been on Pomalyst and Dexamethasone chemo treatment (Pom/Dex). On July 16th 2017, my Dexamethasone treatment ended, due to right eye damage, reported by my Glaucoma Specialist, from long-term use. On January 9th, 2018 I began Ninlaro chemo to combat steadily rising cancer levels. On July 23rd, dexamethasone (40mg) was added to my Ninlaro and Pomalyst chemo treatment, due to excessively high cancer levels.
Weekly chemo-inspired self-portraits can be viewed in my flickr album.